Image: Sanofi Pasteur [CC BY-NC-ND 2.0], via Flickr
Cutting-edge vaccine platform among technology company’s ambitions
South Africa announced a multi-billion rand health research partnership on 23 September. The deal, with United States-based company NantWorks, will focus on Covid-19 vaccines, cancer, and infectious diseases.
“We are committed to invest and support R3 billion. That is the beginning of what would be needed,” said Patrick Soon-Shiong, the South Africa-born head of NantWorks, during the launch webinar. R3bn is about US$200 million.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.